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Background. A novel coronavirus identified in 2019 leads to a pandemic of severe acute respiratory distress syndrome with
important morbidity and mortality. Initially, children seemed minimally affected, but there were reports of cases similar to
(atypical) Kawasaki disease or toxic shock syndrome, and evidence emerges about a complication named paediatric inflammatory
multisystem syndrome temporarily associated with SARS-CoV-2 (PIMS-TS) or multisystem inflammatory syndrome in children
(MIS-C). Case Presentations. Two cases were compared and discussed demonstrating varying presentations, management, and
evolution of MIS-C. ,ese cases are presented to increase awareness and familiarity among paediatricians and emergency
physicians with the different clinical manifestations of this syndrome. Discussion.MIS-C may occur with possible diverse clinical
presentations. Early recognition and treatment are paramount for a beneficial outcome.
1. Introduction
In December 2019, a novel coronavirus was identified in
Wuhan (China) as the cause of an atypical pneumonia which
may cause severe acute respiratory distress syndrome. ,e
virus rapidly spread around the world and became a global
pandemic. ,e virus was named “severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)” by the World
Health Organization.,e disease has been termed “COVID-
19” [1].
In Belgium, the first case was diagnosed in February
2020. During the following months, more information be-
came available about the course of the disease. In children, a
SARS-CoV-2 infection is usually asymptomatic or mild [2].
However, more reports emerged of a presentation in chil-
dren similar to Kawasaki disease or toxic shock syndrome
[3, 4]. ,e syndrome has been named multisystem
inflammatory syndrome in children (MIS-C), paediatric
multisystem inflammatory syndrome, paediatric inflam-
matory multisystem syndrome temporarily associated with
SARS-CoV-2 (PIMS-TS), or paediatric hyperinflammatory
syndrome [5] and has been defined by the CDC (see Table 1)
and the WHO (see Table 2) [6, 7].
In our tertiary teaching hospital, we detected two cases of
MIS-C that are worthwhile comparing, discussing, and
sharing with the wider paediatric community, in order to
optimize early recognition and management of MIS-C.
Both patients provided informed consent, and approval
of the Ethical Committee was granted.
2. Case Presentation 1
,e first case concerns a 15-year-old boy, known with id-
iopathic end-stage kidney disease (ESKD) treated with
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peritoneal dialysis. He had no history of cardiac dysfunction.
He was admitted on March 6th, 2020, for a deceased-donor
kidney transplantation which was postponed because of
fever for 3 days. He complained of fatigue, headaches, and
loss of appetite. Characteristics and laboratory findings at
admission and imaging results are noted in Table 3. A
positive PCR for SARS-CoV-2 confirmed COVID-19 the
day of admission. He was hospitalized for 10 days because
isolation measures were not possible at home. He stayed
paucisymptomatic and received supportive care with anti-
pyretics besides his usual treatments for kidney failure. After
10 days, he was discharged home.
Twenty-three days after discharge, he was readmitted
because of dyspnea (NYHA grade III), orthopnea, and he-
moptysis. Laboratory findings and imaging results are shown
in Table 3. Because of suspected alveolar hemorrhage,
bronchoscopy was performed the day after admission. Re-
peated bronchoalveolar lavage ruled out alveolar bleeding.
SARS-CoV-2 PCR on lower respiratory samples was negative.
Because of progressive oxygen requirements after bron-
choscopy and severe myocardial dysfunction on echocardi-
ography, the patient was transferred to the intensive care unit
for monitoring, inodilator therapy, and noninvasive venti-
lation (NIV) with rapid clinical recovery. NIV could be
stopped, and supplemental oxygen was given by high-flow
nasal cannula until day 4 of hospitalization. Endomyocardial
biopsy was performed, but neither endomyocardial PCR nor
histopathological analysis was suggestive for SARS-CoV-2
myocarditis. Cardiac MRI on day 8 revealed a dilated left
ventricle with reduced ejection fraction of 30–35%. Coro-
narography revealed normal coronal anatomy.
While titrating heart failure therapy, he needed readmission
in the medium care unit from day 9 to 12 because of an episode
of relapse cardiac decompensation that needed to be managed
by increasing ultrafiltration through peritoneal dialysis.
Between day 18 and 20, he developed a low-degree fever
(maximum body temperature of 38.7°C axillary). C-reactive
protein was low, and lymphocytosis was absent. Because of the
suspicion of pneumonia, co-amoxiclav was empirically started.
All cultures (blood, sputum, peritoneal fluid, and urine)
yielded negative. Because of nocturnal hypoxemia, a poly-
somnography was performed revealing Cheyne–Stokes apneas
secondary to heart failure. After 28 days, he was ready for a
new discharge home.He is still undermedical follow-up for his
end-stage kidney disease and slowly recovering heart failure.
,is patient was one of the first cases of paediatric SARS-
CoV-2 infection in Belgium. In retrospect, we think he was
one of the first cases of a MIS-C associated with a SARS-
CoV-2 infection in Europe, with signs of viral or inflam-
matory myocarditis. At that time, little was known about the
treatment of a MIS-C associated with COVID-19 infection,
so no immunoglobulins or corticoids were administered
during his stay.
3. Case Presentation 2
,e second case, a girl of 14 years old, known with Len-
nox–Gastaut syndrome, was admitted on April 28th, 2020, in
our hospital for neurological observation after a severe
concussion. ,e second day of admission, she developed
high fever initially not responding to antipyretics, and she
became generally unwell with a dry cough. ,e patient and
her mother had COVID-19-like symptoms approximately a
month prior to admission; unfortunately, no confirmation
with PCR-testing for SARS-CoV-2 was obtained at that time.
Additional characteristics, laboratory findings, and chest
X-ray results are shown in Table 3.
Epileptic activity increased, and she needed seizure
medication. Because of seizures and the risk of aspiration
pneumonia, intravenous co-amoxiclav was empirically ini-
tiated. She gradually deteriorated needing oxygen therapy.
Because fever persisted and inflammation parameters were
rising, intravenous antibiotic therapy was switched to third
generation cephalosporins. Cardiac ultrasound, ECG, and
Table 1: Definition of MIS-C by the CDC [6].
(1) An individual aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness
requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal,
dermatologic, or neurological)
(2) AND no alternative plausible diagnoses
(3) AND positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test, or COVID-19 exposure within the 4
weeks prior to the onset of symptoms
Table 2: Definition of MIS-C by the WHO [7].
(1) Children and adolescents 0–19 years of age with fever >3 days
(2) AND two of the following:
(i) Rash or bilateral nonpurulent conjunctivitis or mucocutaneous inflammation signs (oral, hands, or feet)
(ii) Hypotension or shock
(iii) Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated
troponin/NT-proBNP)
(iv) Evidence of coagulopathy (by PT, PTT, and elevated D-dimers)
(v) Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain)
(3) AND elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin
(4) AND no other obvious microbial cause of inflammation, including bacterial sepsis and staphylococcal or streptococcal shock
syndromes
(5) AND evidence of COVID-19 (RT-PCR, antigen test, or serology positive) or likely contact with patients with COVID-19
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Table 3: Comparing clinical signs and symptoms, lab and imaging, and treatment and outcome for two cases of MIS-C.
Case 1 Case 2
Characteristics
Gender Male Female
Age (years) 15 14
1st admission 2nd admission
Weight (kg) 60 67 50
BMI (kg/m2) 19.59 21.88 34.72
Signs and symptoms
Fever Yes No Yes
Cough, dyspnea Yes Yes Yes
Sore throat No No Yes
Decreased appetite No Yes Yes
Nausea, vomiting No No No
Diarrhoea No No Yes
Fatigue Yes Yes Yes
Headache Yes No Yes
Rash Yes No Yes
Desaturation <92% No Yes Yes
Edema No Yes Yes
PICU referral
Reason of referral No PICU referral Respiratory deterioration Respiratory distress and excessive edemawith early signs of shock







LOS in hospital 10 28 23
LOS in PICU 0 7 10
Imaging result
Chest X-ray Normal Bilateral consolidations Consolidation left upper lobe
Chest CT No Bilateral consolidations Pericarditis and bilateral consolidations
Heart ultrasound No
(i) Dilated left ventricle, ejection
fraction 30–35%.
(ii) Diastolic dysfunction grade 1
(iii) Normal right ventricle
(iv) Dilated left atrium
(v) MI 2/4, TI 1/4, dilated truncus
pulmonalis
(vi) Pericardial effusion (5mm), no
hemodynamical consequences
(i) Pericarditis with pericardial effusion
15mm, no hemodynamical
consequences
ECG Normal Negative T-waves in the anterior wallwith prolonged QT-segment (534ms)
Peripheral low voltages with flattened T-





(iii) CRP 30mg/L (maximum)
(iv) Albumin 31 g/L
(v) Normal hepatic enzymes
(i) No lymphopenia/leukopenia
(ii) No thrombocytopenia or
thrombocytosis
(iii) Anemia: hemoglobin 7.3 g/dL
(iv) CRP 56.6mg/L
(v) Albumin 26 g/L
(vi) Normal hepatic enzymes
(vii) Cardiac enzymes:
(a) NT-proBNP 155919.0 ng/L
(b) Cardiac troponin T 0.314 µg/L




(iii) Hemoglobin 7.6 g/dL
(iv) CRP 304.3mg/L (maximum)
(v) Albumin 24 g/L
(vi) Cardiac enzymes:
(a) NT-proBNP 3228.0 ng/L
(b) Cardiac troponin 0.01 mcg/L
(vii) D-dimer 3584 ng/ml
(viii) Fibrinogen 322mg/dL
Microbiology results (i) Nasopharyngeal swab: PCRSARS-CoV-2 positive
(i) Nasopharyngeal swab: PCR SARS-
CoV-2 negative
(ii) Heart biopsy: PCR SARS-CoV-2
negative
(iii) SARS-CoV-2 IgG ELISA positive
(54.30 AE/mL)
(i) Nasopharyngeal swab: PCR SARS-
CoV-2 negative (twice)
(ii) SARS-CoV-2 IgG ELISA positive
(41.30 AE/mL)
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echocardiography were planned, as well as a chest CTwhich
all showed signs of pericarditis (see Table 3).
Our patient did not meet the criteria for Kawasaki
disease but appeared to be an atypical Kawasaki-like shock
syndrome. A trial of intravenous immunoglobulins (IVIGs)
was administered. Although none of the cultures (blood,
cerebrospinal fluid, urine, stool, and bronchial aspirates)
yielded positive, antibiotics were continued for 10 days.
Shortly after IVIG treatment, the patient clinically improved
significantly although moderate fever persisted and in-
flammatory parameters dropped swiftly (as visualized in
Figure 1). Oxygen therapy was interrupted, and all edema
disappeared. In the light of clinical and laboratory im-
provement to normalization, there seemed no need for
additional corticotherapy.
After hospital discharge, SARS-CoV-2 serology returned
positive and diagnosis of MIS-C associated with COVID-19
was confirmed. She remains under medical follow-up for her
epilepsy but recovered completely from PIMS-TS.
4. Discussion
Multisystem inflammatory syndrome in children (MIS-C) is
an uncommon entity. During this global pandemic with
SARS-CoV-2, some paediatric cases emerged demonstrating
a formerly unknown complication of COVID-19, meeting
criteria of typical or atypical Kawasaki disease, toxic shock
syndrome, and macrophage activation syndrome [3, 8, 9].
Our cases fulfilled the definition of MIS-C, as described by
the Centre for Disease Control (CDC) in the USA [6] or by
the World Health Organization (WHO) [7].
It is noteworthy that these new developing cases are
generally older (teenagers) than the typical Kawasaki patient,
who is generally younger than six years old.
Comparing the two cases in this study with other cases
described in the literature, we note that MIS-C is mostly
described in patients with following characteristics: young
adolescents, African origin, and BMI >25 kg/m2 [3, 8, 10].
Our cases absolutely match those characteristics. Both cases
were young teens of African origin; patient 1 had a normal
BMI, whereas patient 2 had a BMI above 95th percentile.
Although the basic features are similar in our two patients,
there is a variation in clinical presentation: Case 1 presented
with respiratory distress and heart failure, whereas patient 2
presented with symptoms similar to toxic shock syndrome.
In the literature, a wide variety of clinical presentations is
described although they have the same underlying entity
[3, 8]. Pathogenesis is not yet fully understood.
Early recognition of MIS-C is paramount for a bene-
ficial outcome, but recognition is complicated by the wide
variety in initial clinical presentation and difficulties in
interpretation of additional investigations. During the
COVID-19 pandemic, high suspicion should be raised in
every child presenting with signs of sepsis or vasculitis. In
those children, additional investigations to confirm in-
fection with SARS-CoV-2 are indicated; however, they are
not always sensitive: with a sensitivity of only 71–98%, a
negative PCR for SARS-CoV-2 does not rule out a SARS-
CoV-2 infection [3, 9, 11]. Patient 2 had a negative PCR
twice, but serology confirmed diagnosis. ,is patient did
have a possible COVID-19 exposure a few weeks prior to
admission. As described in the literature, MIS-C can occur
in the acute phase of COVID-19 but also as a post-
inflammatory syndrome [12]. Although chest CT in acute
COVID-19 in adults is very sensitive [13], imaging of the
chest in children with MIS-C can be normal [8, 10]. Close
cardiac monitoring is warranted although cardiac ultra-




























































































































































Figure 1: Course of C-reactive protein in Case 2 in the year 2020.
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sampling of cardiac enzymes should be done in every child
with suspicion of MIS-C [4]. ,is often shows elevation of
D-dimers, NT-proBNP, troponins, and fibrinogen, as seen
in our first case (fibrinogen in the second case was not
tested in the acute phase of disease) [14]. ,ese laboratory
results are not often seen in typical Kawasaki which can
help guide diagnosis.
In treating MIS-C, a multidisciplinary approach is de-
sirable as all organ systems can be involved and associated
morbidity and mortality is described in the literature [3, 8].
Antibiotic therapy is often initiated because of the
clinical resemblance to toxic shock syndrome and sepsis and
the high inflammatory parameters. Both patients in this
study were empirically started on antibiotics as per sepsis
protocol, but in both cases all cultures yielded negative.
,us, in suspicion of MIS-C, antibiotics can be stopped early
if cultures stay negative after 48 hours.
In MIS-C, imminent treatment with intravenous
immunoglobulins is associated with a beneficial out-
come. In our cases, patient 2 showed swift improvement
with IVIG alone. Case 1 did not receive any treatment
other than supportive treatment. We can only speculate
that additional treatment might have improved his
course of disease and length of hospital stay. Suggested
management in other case reports includes intravenous
immunoglobulins or corticoids [3, 12]. In one case re-
port, the patient was treated with tocilizumab, an IL-6
receptor antagonist [10]. A study published in April 2020
showed significant clinical improvement after adminis-
tration of tocilizumab to patients with COVID-19
pneumonia associated with acute respiratory distress
syndrome [9].
We are convinced that sharing the features in this subset
of children will enhance the awareness for MIS-C in the
wider paediatric community and may help to optimize early
recognition and management of this novel syndrome.
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